Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to neridronic acid and alendronic acid. Pamidronic acid was first described in the literature in 1977. The second generation bisphosphonates are less common as third generation bisphosphonates, such as ibandronic acid, zoledronic acid, minodronic acid, and risedronic acid are ...
Pamidronate is indicated to treat moderate to severe hypercalcemia of malignancy, moderate to severe Paget's disease of bone, osteolytic bone metastases of breast cancer, and osteolytic lesions of multiple myeloma.
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States
Washington University Medical School-St. Louis Children's Hospital, St. Louis, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.